Carbamazepine-induced liver injury

Area of Science:

• Hepatology
• Clinical Pharmacology
• Toxicology

Background:

• Carbamazepine is an anticonvulsant medication with known potential for idiosyncratic adverse drug reactions.
• Liver injury is a rare but serious side effect associated with carbamazepine use.
• Understanding the spectrum of carbamazepine-induced liver injury (CILI) is crucial for timely diagnosis and management.

Observation:

• This report details two cases of patients experiencing liver injury attributed to carbamazepine.
• Clinical, biochemical, and histological findings were analyzed to characterize the liver damage.
• One patient presented with features suggestive of idiosyncratic hypersensitivity hepatitis, including granulomas.

Findings:

• The second patient's liver injury pattern mimicked that of a direct hepatotoxin.
• Both cases demonstrated a rapid and complete recovery of liver function after carbamazepine withdrawal.
• Histological examination provided key insights into the distinct mechanisms of injury in each case.

Implications:

• These findings underscore the diverse clinical presentations of carbamazepine-induced liver injury.
• Prompt drug discontinuation is critical for favorable outcomes in CILI.
• Further research into the immunopathogenesis of CILI may aid in predicting and preventing such reactions.